Show simple item record

dc.contributor.authorDirnagl, Ulrich
dc.contributor.authorFisher, Marc
dc.date2022-08-11T08:09:28.000
dc.date.accessioned2022-08-23T16:31:51Z
dc.date.available2022-08-23T16:31:51Z
dc.date.issued2012-06-01
dc.date.submitted2013-02-01
dc.identifier.citationJ Cereb Blood Flow Metab. 2012 Jun;32(6):933-5. doi: 10.1038/jcbfm.2012.51. <a href="http://dx.doi.org/10.1038/jcbfm.2012.51" target="_blank">Link to article on publisher's site</a>
dc.identifier.issn0271-678X (Linking)
dc.identifier.doi10.1038/jcbfm.2012.51
dc.identifier.pmid22510602
dc.identifier.urihttp://hdl.handle.net/20.500.14038/37749
dc.descriptionRepublished in: Stroke. 2012 Jun;43(6):1453-4. doi: 10.1161/STROKEAHA.112.653709.
dc.description.abstractTranslational stroke research is in a crisis, and pharmaceutical companies continue to exit the field. Many reasons for the apparently insurmountable barrier between the bench and bedside in stroke drug development have been identified. It is time to act now to bridge the gap between preclinical and clinical studies of purported new therapies. We strongly believe that it is too early to abandon translational stroke research.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=22510602&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1038/jcbfm.2012.51
dc.subjectHumans
dc.subjectMulticenter Studies as Topic
dc.subjectRandomized Controlled Trials as Topic
dc.subject*Stroke
dc.subject*Translational Medical Research
dc.subjectNervous System Diseases
dc.subjectNeurology
dc.titleInternational, multicenter randomized preclinical trials in translational stroke research: it's time to act
dc.typeEditorial
dc.source.journaltitleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
dc.source.volume32
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/neuro_pp/423
dc.identifier.contextkey3640718
html.description.abstract<p>Translational stroke research is in a crisis, and pharmaceutical companies continue to exit the field. Many reasons for the apparently insurmountable barrier between the bench and bedside in stroke drug development have been identified. It is time to act now to bridge the gap between preclinical and clinical studies of purported new therapies. We strongly believe that it is too early to abandon translational stroke research.</p>
dc.identifier.submissionpathneuro_pp/423
dc.contributor.departmentDepartment of Neurology
dc.source.pages933-5


This item appears in the following Collection(s)

Show simple item record